ARPO Aerpio Pharmaceuticals Inc.

2.95
-0.32  -10%
Previous Close 3.27
Open 3.35
Price To Book 1.8
Market Cap 119734612
Shares 40,588,004
Volume 125,938
Short Ratio
Av. Daily Volume 126,937

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 multiple ascending dose data due 1Q 2019.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 2 completion of dosing announced January 17, 2019 with data due March 2019.
AKB-9778 - TIME 2B
Non-Proliferative Diabetic Retinopathy

Latest News

  1. Aerpio (ARPO) Jumps: Stock Rises 7.8%
  2. Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
  3. Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever
  4. Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
  5. Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update
  6. Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
  7. Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018
  8. Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
  9. Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
  10. The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
  11. Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update
  12. Aerpio Pharmaceuticals, Inc. to Host Earnings Call
  13. Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018
  14. Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock
  15. Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
  16. Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
  17. Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
  18. Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease